Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CD5 Gene Signature Identifies Diffuse Large B-Cell Lymphomas Sensitive to Brutonʼs Tyrosine Kinase Inhibition

11 Dec 2023

Abstract excerpt

PURPOSE: A genetic classifier termed LymphGen accurately identifies diffuse large B-cell lymphoma (DLBCL) subtypes vulnerable to Bruton's tyrosine kinase inhibitors (BTKis), but is challenging to implement in the clinic and fails to capture all DLBCLs that benefit from BTKi-based therapy. Here, we developed a novel CD5 gene expression signature as a biomarker of response to BTKi-based therapy in DLBCL. METHODS:...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Chronic Lymphocytic Leukemia Research
Share to Lymphoma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38079587
DOI: 10.1200/jco.23.01574

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CD5 Gene Signature Identifies Diffuse Large B-Cell Lymphomas Sensitive to Brutonʼs Tyrosine Kinase InhibitionPMID 38079587Read ↗

Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell LymphomaSemantic proximity Read ↗

Simplified algorithm for genetic subtyping in diffuse large B-cell lymphomaSemantic proximity Read ↗

Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma.Semantic proximity Read ↗

Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes.Semantic proximity Read ↗

LymphGen-Sig: Integrating genetic and transcriptional states to predict therapeutic response in DLBCLSemantic proximity Read ↗

High-grade B-cell lymphoma, not otherwise specified: an LLMPP studySemantic proximity Read ↗

Distribution and prognostic impact of LymphGen subtypes in Korean diffuse large B-cell lymphoma using clinical NGS panel.Semantic proximity Read ↗

High-grade B-cell lymphoma not otherwise specified, with diffuse large B-cell lymphoma gene expression signatures: Genomic analysis and potential therapeutics.Semantic proximity Read ↗

Molecular Determinants of Clinical Outcomes In a Real-World Diffuse Large B-cell Lymphoma PopulationSemantic proximity Read ↗

Pathogenesis of diffuse large B cell lymphoma proteogenotypes.Semantic proximity Read ↗

Are there clinically relevant prognostic factors in diffuse large B-cell lymphoma beyond International Prognostic Index?Semantic proximity Read ↗

Using Informatics Tools to Identify Opportunities for Precision Medicine in Diffuse Large B-cell Lymphoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.